We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Former GSK Employee Sues Drugmaker Over Wrongful Termination
Mylan Strikes Biosimilars Deal With Momenta Worth Up To $245M
Caladrius Biosciences to Discontinue Phase 3 Melanoma Study
FDA Recalls Shakti’s Compounded Asafoetida Powder
C4 Partners With Roche to Develop Targeted Protein Degradation Treatments Read More
To reduce medication errors, CDER on Friday released its revised policies and procedures on proprietary naming of drugs, which are sometimes misidentified because of the way they are spelled or how the names sound. Read More
Two House members are asking two embattled drugmakers for information and documents related to some of their products ahead of a Jan. 26 hearing on prescription drug pricing. Read More
J&J Licenses Hep B Treatments from Chinese Drugmaker
Stealth BioTherapeutics Wins Fast Track Designation for MTP-131
Galera Snatches Up FDA Fast Track for Oral Mucositis Candidate
Checkpoint Licenses Cancer Therapies from Teva
BLA Expected in Early 2016 After Dynavax’s Hepatitis B Vaccine Meets Primary Endpoints Read More
Drugmakers have asked the FDA to think “globally” with the international community as they weighed in on the agency’s draft guidance on established conditions for reporting chemical, manufacturing and control changes. Read More